Affimed N.V. (NASDAQ:AFMD) Q1 2019 Earnings Conference Call Transcript

May 22, 2019 • 08:30 am ET


Affimed N.V. (NASDAQ:AFMD) Q1 2019 Earnings Conference Call Transcript


Loading Event

Loading Transcript


Good day and welcome to Affimed First Quarter 2019 Financial Results and Corporate Update Conference Call. At this time all participants are in a listen-only mode. As a reminder, today's conference is being recorded.

I'll now introduce your host for today's conference Greg Gin, Head of Investor Relations, Affimed. Please go ahead.

Gregory Gin

Thank you Serena. Thank you for joining us today for Affimed's Conference Call to discuss the Company's First Quarter 2019 Financial Results and Operational Progress. This morning Affimed issued a press release which is posted on the Company's website at

On the call with me today are Adi Hoess, Chief Executive Officer of Affimed; Florian Fischer, Chief Financial Officer; also with us on today's call and available for questions are Leila Alland, Chief Medical Officer and Wolfgang Fischer, Chief Operating Officer who oversees our regulatory efforts. We will begin today's call with opening remarks from Adi on our strategic focus and progress during the first quarter. And then Florian will review the financial results. Following the prepared remarks, we will host the Q&A session.

Before we start let me review our safe harbor statement. Today's discussion contains projections and forward-looking statements regarding future events. These statements represent our beliefs and assumptions only as of the date of this discussion. Except those required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons why the actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

These forward-looking statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including but not limited to those identified under the section entitled Risk Factors in our filings with the SEC and those identified another section entitled cautionary statement regarding forward-looking statements in our Form-6K filed with the SEC earlier today.

With that I will now turn the call over to Adi.

Adi Hoess

Thanks Greg, good morning everyone and thank you for being with us. Affimed intent is to broaden its leadership position in innate immunity based cancer therapies. We therefore conducted a strategic review of our development programs. We assess the target disease indications and unmet medical needs, commercial opportunities as well as the clinical and regulatory paths to approval. Following completion of this internal review, we believe even more strongly that our innates and engagers have the potential to transform current immuno-oncology approaches.

By actualizing the untapped potential of the innate immune system to give patients back their innate ability to fight cancer. Thereby addressing unmet patients needs in treating hematologic and solid tumor malignancies. As a result, we have determined that the optimal use of our resources at this time is to focus our research and development investments on advancing ongoing and previously announced clinical trials for our CD16A-targeting innate cell engager candidates, including AFM13 and AFM24.

In line with a strategic focus on our innate immunity portfolio,